Nanobiotix Unveils Promising Results from Phase 1 Study on NBTXR3
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX) has recently announced encouraging results from their Phase 1 study investigating JNJ-1900 (NBTXR3) in conjunction with immune checkpoint inhibitors for patients battling primary cutaneous melanoma resistant to anti-PD-1 therapies. This study is particularly significant as it focuses on a challenging population of patients who have exhausted available treatment options.
Key Findings from the Study
The data revealed a favorable safety profile alongside early efficacy signals within a heavily pretreated cohort whose cancer had progressed following multiple therapy lines, including anti-PD-1 treatments. The recommended phase 2 dose for this novel therapy was established at 33% of gross tumor volume (GTV).
Efficacy Metrics
The study reported an impressive best observed objective response rate (ORR) of 47.4% across all lesions, according to RECIST 1.1 criteria. Additionally, a notable disease control rate (DCR) of 78.9% was achieved, highlighting the potential of JNJ-1900 (NBTXR3) in effectively managing tumor response in melanoma patients.
Overall Survival Insights
Patients treated in the study exhibited a median overall survival (mOS) spanning 14.6 months, which adds to the promising nature of this therapy. Investigators of the study concluded that these significant findings warrant further exploration through randomized clinical trials, potentially offering a new treatment alternative for melanoma patients who are either naive or refractory to anti-PD-1 therapies.
Safety and Patient Feasibility
The safety of JNJ-1900 (NBTXR3), combined with immune checkpoint inhibitors like pembrolizumab or nivolumab, was evaluated across all patient responses. Findings indicated that the administration was feasible at the recommended dose, with injection-related adverse events being manageable.
Summary of Safety Profile
Out of the 21 patients involved in the trial, 16 experienced varying degrees of treatment-emergent adverse events (TEAEs), yet the overall therapeutic regimen maintained a favorable safety outlook. Notably, only one patient reported severe side effects classified as grade 3+, underscoring the treatment's potential tolerability.
Future Directions for Nanobiotix
Amidst these encouraging results, Nanobiotix is committed to advancing JNJ-1900 (NBTXR3) through further studies. Chief Medical Officer Louis Kayitalire highlighted the treatment's potential, indicating a relationship between localized tumor response and systemic regression could point towards a re-activation of the immune response in these patients.
Upcoming Conference Call
To disseminate these findings further, Nanobiotix plans to conduct a conference call to discuss this data in detail. Participants can expect insight from CEO Laurent Levy on the implications of these results and future development pathways for JNJ-1900 (NBTXR3).
About JNJ-1900 (NBTXR3)
JNJ-1900 (NBTXR3) stands out as a first-in-class oncology product utilizing functionalized hafnium oxide nanoparticles. Its innovative mechanism is prompted by radiotherapy, which activates significant tumor cell death, thereby stimulating an adaptive immune response. As this therapy is progressively evaluated across various solid tumor types, promising collaborations are fast-tracking the development of NBTXR3 in congress with existing therapies.
Company Overview
Established in 2003, Nanobiotix is committed to transforming treatment paradigms for patients through pioneering physics-based therapeutic approaches. With a robust patent portfolio, Nanobiotix focuses on advancing therapies that could revolutionize the management of solid tumors and other significant health issues, bolstered by their mission to extend human life possibilities.
Frequently Asked Questions
What are the main findings of the Phase 1 study on JNJ-1900?
The study showed a favorable safety profile and early efficacy signals, with a 47.4% ORR and a 14.6-month median overall survival.
What is the recommended phase 2 dose of JNJ-1900?
The recommended phase 2 dose is established at 33% of the gross tumor volume.
What safety concerns were raised during the study?
Most patients experienced mild to moderate side effects, with only one patient affected by a severe adverse event.
What is the significance of the treatment for melanoma patients?
This treatment offers a potential new option for patients who are resistant to current therapies which significantly broadens treatment avenues.
When will the conference call regarding these findings occur?
The conference call is scheduled for September 18, 2025, at 8:00 AM EDT.
